JD.com, Inc. (JD)

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: USD 30.60 (as of 2026-07-21)

JD.com, the Chinese e-commerce and logistics giant, has spent roughly 18 months rangebound between $25 and $48 — down more than 70% from its 2021 all-time high near $108 — as a costly instant-retail and food-delivery price war against Meituan and Alibaba compressed consolidated operating margin from 3.3% to near breakeven. The core retail business is quietly improving (JD Retail's own operating margin expanded to 5.6% in Q1 2026), Chinese regulators intervened in June 2026 to cap the subsidy war, and management guides to roughly halving the New Businesses loss in Q2 2026 — but the stock also carries a fresh, unresolved overhang from a Beijing regulator's 618-festival advertising review and the resulting US securities-fraud law-firm investigations. No voice on the panel argues the underlying business is broken; the debate is entirely about timing and confirmation — two frameworks are already buying on the net-cash-adjusted valuation gap, while the rest want the technical trend, the earnings trajectory, or the legal cloud to clear first. With multiple specific, dated triggers still pending and no dissenting SELL case anywhere in the panel, the synthesis is WAIT.

Key levels

Key resistance starts at $32.03 — the weekly Supertrend level that needs to flip before the technical picture turns constructive — then $35-36 (the former 2022 range low, now overhead supply), up to $45-48 where the failed mid-2025 rally topped out. Key support sits at $28-29 (a Fibonacci shelf from the 2024-2025 advance), then the $25 multi-year range floor, with $20 as the next round-number level should that floor break. The analyst consensus target spans USD 35 to 43, averaging near USD 40 — meaningfully above the current price, broadly consistent with the panel's own net-cash-adjusted valuation estimates, though the technical and macro lenses want price/trend confirmation before crediting that gap.

What legendary investors think

We ran JD.com past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Does the food-delivery loss-narrowing trend confirmed in one quarter continue through Q2 2026 and clear the fresh 618-advertising legal overhang — unlocking the re-rating the net-cash-adjusted valuation implies — or does China's soft consumer backdrop and an unresolved investigation keep the stock rangebound for another cycle?

The numbers

Metric	Value
Price / Market cap	USD 30.60 / ~41.3B
P/E (TTM / fwd)	23.14x / 8.72x
ROE	6.0%
Operating margin	~1.2% (Q1 2026, consolidated; JD Retail segment alone ~5.6%)
Dividend yield	~3.3%
Debt / equity	~0.38x
Free cash flow	~USD 2.6B (TTM)

Figures as of Q1 2026 (reported May 2026) / July 20–21, 2026; sourced from JD.com Inc. IR/SEC 6-K filings, stockanalysis.com, GuruFocus. Consolidated operating margin reflects heavy Q1 2026 investment in the New Businesses (food-delivery/instant-retail) segment; some third-party aggregators reported conflicting trailing free-cash-flow figures (a range of roughly $2.6B–$5.6B) — the lower, more granular figure is used here. Next print: Q2 2026 earnings, expected mid-August 2026.

The bottom line

The next hard confirmation point is the Q2 2026 print, expected mid-August — watch specifically whether New Businesses losses narrow roughly in line with management's own guidance of a 50% sequential reduction, and whether JD Retail's operating margin holds near its Q1 high. Resolution, in either direction, of the SAMR 618-advertising review and the related US securities-fraud law-firm investigations is a second, less predictable catalyst that could move the stock independent of the fundamentals. On the technical side, a weekly close back above $32.03 on confirmed volume is the specific trigger several panel voices are waiting on before treating the range as broken to the upside; a close below the $28-29 shelf would instead open the door back toward the $25 multi-year floor. China's monthly retail-sales data — which swung from a rare year-over-year decline in May 2026 to a rebound in June — remains the macro variable most likely to override company-specific catalysts either way.

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: USD 30.19 (as of 2026-07-25)

What changed since 2026-07-21:

• Price drifted essentially sideways: USD 30.60 → USD 30.19, a change of (30.19 − 30.60) / 30.60 = −1.34% — consolidation, not a directional move.
• Panel composition held exactly steady: two Bullish voices (Medium and Medium-High conviction), four Neutral voices (Low to Medium conviction) — same split, same conviction levels as the 2026-07-21 read.
• New catalyst (negative): the European Commission issued a formal Statement of Objections in its Foreign Subsidies Regulation probe into JD's $2.5B Ceconomy bid on 2026-07-22, with a ruling due 2026-10-02.
• New catalyst (offsetting positive): JD.com became Costco China's exclusive official e-commerce platform partner on 2026-07-22, expanding the flagship store (~700 SKUs) with same-day nationwide fulfillment — reinforcing the core retail/logistics moat the panel already credits.
• Analyst consensus firmed modestly: the average target moved from last week's USD 35–40–43 span to roughly USD 39.5–41.3, still Strong-Buy-leaning, with fresh reiterations since 07-21 (Barclays $41, HSBC $39).
• Technical structure: five consecutive higher weekly closes off the 2026-06-22 low ($25.39), but the stock is once again stalling right at the same $31.50–32.50 zone that rejected two prior 2026 rallies (04-13 and 05-11) — no fresh breakout, no fresh breakdown, and rally volume remains average rather than expanding.
• Verdict line: unchanged at WAIT / MEDIUM — nothing this week resolved either of the two hard triggers the panel is waiting on.

None of the six frameworks moved position this week. The Intrinsic-Value Modeler (#investor-2026-07-25-the-intrinsic-value-modeler) and Forensic Skeptic (#investor-2026-07-25-the-forensic-skeptic) remain bullish on the same net-cash-adjusted valuation gap, arguing a quiet week of unresolved legal headlines with no new findings behind them doesn't change a DCF or a balance-sheet floor. The GARP Operator (#investor-2026-07-25-the-garp-operator) is still explicitly waiting on the mid-August print before trusting a PEG built on a depressed earnings base, and now also flags the EU Ceconomy scrutiny as a capital-discipline watch-item. The Moat Compounder (#investor-2026-07-25-the-moat-compounder) still can't get past the VIE structure and reads the EU probe as a bolt-on acquisition complication rather than a core-business threat. The Macro Opportunist (#investor-2026-07-25-the-macro-opportunist) still wants the same volume-confirmed weekly close above $32.03 before turning constructive, noting a renewed US-China tariff truce extension as a modest offset to soft Chinese GDP data. The Disruptive-Innovation Seeker (#investor-2026-07-25-the-disruptive-innovation-seeker) still frames JD as a mature incumbent defending margin with automation rather than a platform-level disruptor. With price flat, the panel's composition unchanged, and both hard triggers — the Q2 print and a confirmed technical reclaim of resistance — still pending, the synthesis stays WAIT.

Key levels

The $31.50–32.50 resistance zone is now reinforced by two live 2026 tests (04-13 high 32.05, close 31.60; 05-11 high 34.30, close 32.01) rather than being theoretical — price is approaching it a third time from below, but without expanding volume behind the approach. Below, the $27.50–29.00 shelf has mostly held on a closing basis through H1 2026 (one modest breach in February, quickly reclaimed), and the $24.50–25.50 band was directly tested on 2026-06-22 (intraweek low 24.55, closed back inside at 25.39) — the freshest, most credible support confirmation in the dataset. $20.00 remains the multi-year floor, untested recently. The analyst consensus target (USD 39.5–41.3, averaging near 40) sits meaningfully above spot, broadly consistent with the panel's own net-cash-adjusted valuation case, though the technical and macro lenses still want price confirmation before crediting that gap.

What legendary investors think

We ran JD.com past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Does the mid-August Q2 print confirm the guided food-delivery loss-narrowing and clear a weekly close above the $31.50–32.50 resistance zone that has now rejected the stock three times — unlocking the re-rating the net-cash-adjusted valuation implies — or does a third open regulatory thread (EU FSR, on top of SAMR and the US securities matters) join the others in keeping the stock rangebound through another cycle?

The numbers

Metric	Value
Price / Market cap	USD 30.19 / ~40.8B
P/E (TTM / fwd)	22.8x / 8.6x
ROE	6.0–6.4%
Operating margin	~1.2% (Q1 2026, consolidated; JD Retail segment alone ~5.6%)
Dividend yield	~3.3%
Debt / equity	~0.38x
Free cash flow	~USD 2.6B (TTM); third-party aggregators diverge sharply (one shows ~$4.9B TTM, another ~$80M for the March-2026 quarter alone) — treat any single figure with caution pending the Q2 print

Figures as of Q1 2026 (reported May 2026) / July 24-25, 2026; sourced from JD.com Inc. IR/SEC 6-K filings, stockanalysis.com, GuruFocus, TipRanks, and financecharts.com. Consolidated operating margin still reflects heavy Q1 2026 investment in the New Businesses (food-delivery/instant-retail) segment. Next print: Q2 2026 earnings, confirmed for 2026-08-13. Secondary dated catalyst: EU Ceconomy Foreign Subsidies Regulation ruling deadline, 2026-10-02.

The bottom line

The Q2 2026 print on 2026-08-13 is still the hard confirmation point the majority of the panel is underwriting against — watch specifically whether New Businesses losses narrow roughly in line with management's guided 50% sequential reduction, and whether JD Retail's operating margin holds near its Q1 5.6% level. A weekly close above the $31.50–32.50 zone on expanding volume remains the specific technical trigger the more cautious voices want before treating the range as broken to the upside; a slide back below the $28.00–29.00 shelf would instead point toward a re-test of the $25.00 support that already held once in June. The newly opened EU Ceconomy FSR probe, due to resolve by 2026-10-02, now sits alongside the still-unresolved SAMR 618 review and US securities-fraud investigations as a third open regulatory thread — no single one of these has yet turned from overhang into adverse finding, but the accumulation of three simultaneous threads is itself a reason several voices are holding conviction steady rather than adding size. What would tip this toward BUY: a confirmed technical breakout paired with a clean Q2 print. What would tip it toward SELL: an adverse finding on any of the three regulatory threads, or a Q2 miss on the guided loss-narrowing.

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: USD 33.01 (as of 2026-08-02)

What changed since 2026-07-25:

• Price: USD 30.19 → USD 33.01 (+9.34%)
• Panel: 2 of 6 → 0 of 6 now Bullish — composition also changed: added The Quality Rationalist, The Structural Tailwind Rider; removed The Macro Opportunist, The Moat Compounder
• Trigger: The panel is watching for either a pullback to USD 28–30 (near the USD 29.80 volume-based support zone), which would offer over 25% margin of safety to The Intrinsic-Value Modeler's USD 37.50 base case, or two consecutive quarters of net margin expansion above 1.5% alongside revenue growth of 5%+, confirming an operational turnaround. On the downside, the level being watched is a weekly close below USD 29.80 (a break of that volume-based support) or a sustained revenue decline below 0% with further margin compression toward 0.5%.
• Verdict: WAIT (unchanged)

Last cycle the panel tilted cautiously bullish with two voices willing to buy into the dislocation at USD 30.19, but the 9.3% rally to USD 33.01 since then has eroded that margin of safety without any confirming fundamental improvement — revenue growth is still ~1%, Q1 2026 net income cratered 53% YoY, and no insider has stepped in to buy. The shift from two mild bulls to zero reflects price moving against the value case faster than the business has moved toward a turnaround, forcing even the constructive voices into a unified wait-for-a-pullback posture.

This is a classic BUY vs WAIT split, not BUY vs SELL. Only the technical scout is a clear buyer at USD 33; the other five voices (The Intrinsic-Value Modeler, The GARP Operator, The Forensic Skeptic, The Quality Rationalist, The Structural Tailwind Rider) all like the asset base and net-cash floor but uniformly want the price near USD 28–30 or a margin-recovery catalyst before committing capital. Nobody is calling SELL on the business itself — the objections are entirely about price and timing. A split between BUY-leaning and WAIT-leaning voices, with no SELL calls anywhere on the panel, synthesizes to a panel-level WAIT rather than HOLD.

Key levels

What legendary investors think

We ran JD.com, Inc. past a panel of 6 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Will JD's net margins stabilize and begin expanding toward even a modest 1.5–2.0% over the next two quarters, or will price competition from PDD and Douyin continue compressing margins toward 0.5%, turning the net-cash floor into the only thing propping up the stock?

The numbers

Metric	Value
Price / Market cap	USD 33.01 / ~USD 37.2B
P/E (TTM / fwd)	17.9x / n/a
ROE	6.12%
Operating margin	n/a
Dividend yield	n/a
Debt / equity	0.50x
Free cash flow	CN¥20.88B

Figures as of 2026-08-01 (price ~USD 30.43 and market cap ~USD 37.2B per Simply Wall St P/S calculation at that date; current price of USD 33.01 reflects the 2026-08-02 close); sourced from GuruFocus, Simply Wall St, TipRanks, and StockAnalysis.com. Free cash flow reported in CNY at source — no USD conversion figure was available to cite.

The bottom line

Watch for JD to retest the volume-based support at USD 29.80 — a weekly close below that level would invalidate the accumulation base and shift the technical picture from constructive to bearish, likely accelerating selling toward the USD 24–26 range where The Intrinsic-Value Modeler's bear case and The Forensic Skeptic's net-asset floor converge. On the upside, the condition that matters is two consecutive quarters of net margin at or above 1.5% (versus today's ~1.0%) paired with revenue growth of at least 5% — that combination would confirm the operational turnaround management has guided for H2 2026 and would justify re-rating the stock toward the USD 39–42 analyst consensus. The Q2 2026 earnings release (expected mid-August) is the next scheduled catalyst where either trajectory could begin to resolve. Until then, the stock sits in a no-man's-land: too cheap for the bears to press given the net-cash floor, yet too rich for the panel to add exposure to given the margin trend.

The panel's take

Verdict: WAIT · Conviction: MED · Last price: 32.97

What changed since 2026-08-02:

• Price: 33.01 → 32.97 (-0.12%)
• Panel: 0 of 6 → 3 of 6 now Bullish — composition also changed: added The Asymmetric Bargainer, The Moat Compounder; removed The Disruptive-Innovation Seeker, The Structural Tailwind Rider
• Trigger: BUY trigger: Q2 2026 earnings (August 13) showing operating margin stabilization or expansion above 2%, combined with continued buyback execution. Alternatively, a pullback to $29.80–$30.68 (volume POC / weekly 50% fib) providing a materially better entry. SELL trigger: continued margin compression without credible path to recovery, or a weekly close below $24.51 invalidating the basing pattern.
• Verdict: WAIT (unchanged)

The verdict holds at WAIT despite the price barely moving (from $33.01 to $32.97), but the panel shifted dramatically: two new voices, The Asymmetric Bargainer and The Moat Compounder, replaced two prior cautious voices, splitting the panel 3-3 between BUY and WAIT where it was previously 0-6 uniformly cautious. The bullish case now has three strong advocates who argue the margin of safety is sufficient today, but the cautious half still demands proof of margin stabilization at August 13 earnings or a pullback toward the $29.80 volume POC before committing capital. The "wait for the fat pitch" logic holds, but the debate is now genuinely contested rather than one-sided.

The split is BUY vs WAIT: the bulls (The Forensic Skeptic, The GARP Operator, The Asymmetric Bargainer) say it's a great business at a deeply discounted price with a fortress balance sheet, while the cautious voices almost all agree the business has merit but cite either a need for a lower entry price (technical-scout wants $29.80, The Intrinsic-Value Modeler wants pullback or catalyst) or a specific catalyst (fundamental-scout, The Moat Compounder, The Quality Rationalist want margin stabilization proof at August 13 earnings). No voice is a genuine SELL. This is a classic WAIT structure: buy the company, not the stock at today's price. The 3 PRICE/TIMING objectors (technical-scout, fundamental-scout, The Intrinsic-Value Modeler) plus 2 BUSINESS-quality skeptics (The Moat Compounder, The Quality Rationalist) create a dominant "wait for the fat pitch" posture rather than a deadlocked HOLD.

Key levels

What legendary investors think

We ran JD.com, Inc. past a panel of 6 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Will JD's operating margins stabilize in Q2 2026 as the sequential-improvement narrative suggests, or is the food-delivery investment cycle, and the brutal competitive dynamics of Chinese e-commerce, a structural margin drag with no visible endpoint?

The bottom line

• Trigger to confirm the breakout: A weekly close above $36.86 on heavy volume would confirm a Stage-2 uptrend, shifting the technical picture from basing to trending and likely drawing in momentum capital that has been waiting on the sidelines.
• The August 13 catalyst: Q2 2026 earnings must show operating margin stabilization or expansion above the current sub-1% level; without at least a sequential improvement, the recovery narrative remains unproven and the WAIT posture extends indefinitely.
• Risk to monitor: A weekly close below $29.80 (the volume point of control where the heaviest accumulation occurred) would invalidate the basing pattern and suggest the market is pricing in structural decline, not a temporary investment cycle.
• Buyback follow-through: If JD sustains the Q1 pace of retiring 1.6% of shares quarterly through H2 2026, the buyback alone creates a meaningful tailwind regardless of margin outcomes. But a slowdown would signal management's own conviction is wavering.
• Further out: If the food-delivery investment cycle demonstrably peaked in H1 2026, operating leverage could drive margins back toward the historical 3.3% over 18–24 months, transforming JD from a value debate into a compounding story. But that requires proof across multiple quarters, not just one print.

The panel's take

Verdict: BUY · Conviction: HIGH · Last price: 29.06 · Changed from WAIT

What changed since 2026-08-08:

• Price: 32.97 → 29.06 (-11.86%)
• Panel: 3 of 6 → 3 of 5 now Bullish — composition also changed: added The Margin-of-Safety Hunter; removed The Forensic Skeptic, The Quality Rationalist
• Trigger: BUY thesis breaks if: (a) Q3 2026 revenue fails to return to positive growth as management explicitly guided, or (b) a weekly close below $24.51 invalidates the basing pattern and signals re-acceleration of the Stage 4 decline. Would upgrade conviction further on a weekly close above $31.25 (monthly EMA20), confirming the Stage 1→Stage 2 transition.
• Verdict: WAIT → BUY

The previous panel leaned WAIT at $32.97 because The Forensic Skeptic and The Quality Rationalist had open concerns about earnings quality and competitive durability. Since then, the stock dropped nearly 12% to $29.06 while management delivered a Q2 print showing a definitive operating-income swing from negative to positive $700 million and explicitly guided for a Q3 revenue recovery. The Forensic Skeptic exited the panel, and the remaining voices — now joined by The Margin-of-Safety Hunter — see a deeper margin of safety at the lower price, flipping the consensus from WAIT to BUY: the business improved, the price got cheaper, and the old skeptics' objections no longer carry a seat at the table.

Five of seven voices are bullish (The Moat Compounder, The Asymmetric Bargainer, The GARP Operator, The Intrinsic-Value Modeler, Fundamental-scout, plus bullish Sentiment-scout), and the bearish dissent is split — Technical-scout wants a better price/timing (PRICE/TIMING objection: likes the business, waiting on $31.25 close), while The Margin-of-Safety Hunter objects on defensive-investor business-quality grounds (no dividend, inconsistent earnings, low current ratio). The Margin-of-Safety Hunter's objection is principled but narrow: it applies only to his strict defensive investor framework — he simultaneously concedes JD trades 35% below The Margin-of-Safety Hunter Number with a massive net-cash cushion and calls it an opportunity for enterprising investors. This is not a genuine SELL split; the cautious voices don't agree with each other, and the bullish side dominates on both fundamentals (PEG 0.27x, FCF yield 10.73%, $16.95/share net cash) and catalysts (management's explicit Q3 revenue-recovery guidance, active $4B buyback, profitability inflection). BUY over WAIT because the business case is overwhelming and the price objection from Technical-scout is a timing preference, not a structural flaw — the fundamental value case ($38-45 intrinsic) dwarfs the $2 overhead supply-zone friction.

Key levels

What legendary investors think

We ran JD.com, Inc. past a panel of 5 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: "Will JD's Q3 2026 revenue actually return to positive growth as management guided, or does the -2.9% contraction signal a structural demand problem in Chinese e-commerce that even record retail margins cannot offset?"

The bottom line

• Catalyst to validate the call: Q3 2026 earnings: management explicitly guided a return to positive revenue growth — actual delivery on that guidance is the single clearest near-term signal this thesis is working.
• Level to confirm the breakout: A weekly close above $31.25 (the monthly EMA20 and top of the overhead supply zone) would confirm a Stage 1-to-Stage 2 transition and likely accelerate the re-rating toward the $38-45 intrinsic value range.
• Risk to monitor: A weekly close below $24.51 would break the developing higher-low basing pattern and suggest the Stage 4 decline is re-accelerating, opening a path toward the $22 bear-case scenario.
• Longer-term margin signal: Watch whether JD Retail's operating margin continues marching toward management's high-single-digit target — even flat revenue combined with 5%+ retail margins would produce earnings growth sufficient to justify a multiple expansion from 9x toward 15x.

The panel's take

Verdict: BUY · Conviction: LOW · Last price: 29.37

Panel: 4 Bullish · 3 Neutral · 0 Bearish → BUY

What changed since 2026-08-15:

• Price: 29.06 → 29.37 (+1.07%)
• Panel: 4 of 5 → 4 of 7 now Bullish — composition also changed: added The Forensic Skeptic, The Structural Tailwind Rider; removed none
• Trigger: Conviction upgrades to HIGH on a monthly close above $31.28 (monthly EMA20), which would confirm the Stage 1→Stage 2 transition the technical scout is waiting for and satisfy the cautious contingent. Conviction also upgrades if Q3 2026 revenue returns to positive growth as management guided, validating the profitability-inflection narrative. The BUY thesis breaks on a weekly close below $24.51 — that would invalidate the basing pattern and reassert Stage 4 decline.
• Verdict: BUY (unchanged)

Since the August BUY call at $29.06, price has barely budged — JD hasn't closed above the monthly EMA20 ($31.28) nor broken below the weekly support at $24.51, so the basing pattern remains intact. The thesis is unchanged but conviction dropped from HIGH to LOW because the technical scout, The Moat Compounder, and The Margin-of-Safety Hunter all flagged that price is stuck below a key moving average, and two new cautious panelists joined without disputing the business story, making the panel split 4-3 on timing rather than fundamentals.

The prior BUY trigger has not fired — JD has not closed above $31.25 on the monthly nor broken below $24.51 on the weekly, and Q3 results are still months away — so the thesis stands, but conviction drops from HIGH to LOW because the technical scout, The Moat Compounder, and The Margin-of-Safety Hunter all flagged that price is stuck below the monthly EMA20 ($31.28) and the Margin-of-Safety Hunter defensive checklist fails on current ratio, trailing P/E, and dividend record. The 4 bullish voices (The Asymmetric Bargainer, The GARP Operator, The Intrinsic-Value Modeler, The Forensic Skeptic) see a profitability inflection at a deeply undervalued 9.2x forward P/E; the 3 neutrals do not dispute the business story but want the monthly close above $31.28 or the Q3 revenue print before committing capital.

Key levels

Key support at $24.51 is the 52-week low and weekly Fib 100% from the $36.86→$24.51 swing — the level that, if broken, invalidates the nascent weekly basing pattern the technical scout identified. Just above price, resistance sits at $30.68 (weekly Fib 50% from the same swing), then $30.98 (monthly Fib 78.6% from the larger $68.29→$20.82 decline), and ultimately $31.28 (monthly EMA20) — the line the cautious contingent needs to see cleared for Stage 1→2 confirmation. The analyst consensus target of $39.66 sits above all near-term resistance and represents the bull case fully playing out.

What legendary investors think

We ran JD.com, Inc. past a panel of 7 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Does JD's profitability inflection — already visible in Q2's operating-income swing and margin expansion — have enough momentum to survive a Chinese consumer that hasn't yet returned to growth, or will the Q3 revenue print expose the margin gains as a one-time cost-cut that the valuation already prices in?

The bottom line

• Trigger to confirm the base: A monthly close above $31.28 (the monthly EMA20) would confirm the Stage 1-to-Stage 2 transition that the cautious contingent is waiting for and would upgrade BUY conviction from LOW to HIGH.
• Next catalyst: Q3 2026 results (mid-November 2026) must show JD Retail revenue returning to positive year-over-year growth as management guided — a miss there would gut the profitability-inflection narrative.
• Risk to monitor: A weekly close below $24.51 would invalidate the basing pattern, reassert the Stage 4 decline, and break the BUY thesis outright.
• Further out: Sustained retail operating margin above 4% for two consecutive quarters would shift the debate from 'can margins improve?' to 'how fast can they compound?', potentially pulling the forward P/E toward 12-15×.